Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.

Also called NCT03346057

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 344 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03346057
  • EudraCT 2017-000187-15
Other papers using this trial's data
  • A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants BMC anesthesiology, 2021-10-28 DOI, PubMed 34711192, PMC8555093 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Denmark, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03346057. Randomized; triple masking; primary purpose treatment. Start 2017-12-20 (actual); primary completion 2019-09-04 (actual). Results posted on 2020-10-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
Condition
Reversal of Neuromuscular Blockade
Intervention (Drug)
Sugammadex 2 mg/kg
Intervention (Drug)
Sugammadex 4 mg/kg
Intervention (Drug)
Sugammadex 16 mg/kg
Intervention (Drug)
Neostigmine + Glycopyrrolate
Intervention (Drug)
Rocuronium
Intervention (Drug)
Vecuronium
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct03346057
Content hash
deb02427309d6f7dd20111fecb5140512aff23e44e8b486a8ae896d02292ec34